Naohiko Seki

38PUBLICATIONS
31CO-AUTHORS
Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Sep 26, 2026
AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation.

|Aug 13, 2026
MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by miR-374b-5p.

|Jul 28, 2026
The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy.

|Jul 28, 2026
MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening.

|Jul 29, 2025
MicroRNA Signatures in Lung Adenocarcinoma Metastases: Exploring the Oncogenic Targets of Tumor-Suppressive miR-195-5p and miR-195-3p.

Yuya Tomioka, Naohiko Seki, Keiko Mizuno

|Dec 27, 2024
Identification of Tumor-Suppressive miR-30a-3p Controlled Genes: ANLN as a Therapeutic Target in Breast Cancer.

Reiko Mitsueda, Ayako Nagata, Hiroko Toda

Pageof 7

Frequent Collaborators

10 joint publications

Hiromasa Inoue

9 joint publications

Katsuhiro Uzawa

7 joint publications

Shunsuke Misono

7 joint publications

Chikashi Minemura